Condition-dependent combination effects with monanchoxymycalin C
Cell-based study · Human 22Rv1 prostate cancer cells [1]
Eight MomC–FR180204 pairs showed two antagonistic and six synergistic combination indices. The first two low-concentration pairs were antagonistic; synergy cannot be generalized across the tested matrix. This is a metabolic viability combination assay, not a biochemical ERK potency measurement or proof of single-agent anticancer selectivity.
| Endpoint | Reported result | Reference |
|---|---|---|
| MTT-derived combination effect: MomC 0.625 µM + FR180204 6.25 µM | Fraction affected; combination index Fa = 0.562; CI = 1.41159 | [1] |
| MTT-derived combination effect: MomC 1.25 µM + FR180204 12.5 µM | Fraction affected; combination index Fa = 0.584; CI = 2.06078 | [1] |
| MTT-derived combination effect: MomC 2.5 µM + FR180204 25.0 µM | Fraction affected; combination index Fa = 0.689; CI = 0.83997 | [1] |
| MTT-derived combination effect: MomC 5.0 µM + FR180204 50.0 µM | Fraction affected; combination index Fa = 0.858; CI = 0.05468 | [1] |
| MTT-derived combination effect: MomC 0.625 µM + FR180204 12.5 µM | Fraction affected; combination index Fa = 0.656; CI = 0.36643 | [1] |
| MTT-derived combination effect: MomC 1.25 µM + FR180204 25.0 µM | Fraction affected; combination index Fa = 0.666; CI = 0.62870 | [1] |
| MTT-derived combination effect: MomC 2.5 µM + FR180204 50.0 µM | Fraction affected; combination index Fa = 0.815; CI = 0.08726 | [1] |
| MTT-derived combination effect: MomC 5.0 µM + FR180204 100.0 µM | Fraction affected; combination index Fa = 0.898; CI = 0.01950 | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- FR180204 6.25–100.0 µM with MomC 0.625–5.0 µM; exact pairs in measurements
- Exposure duration
- 1 h inhibitor/vehicle pretreatment, then 48 h after MomC addition
- Method
- MTT viability followed by Chou–Talalay analysis; 10% FBS/RPMI medium
- Vehicle
- Equal amount of DMSO in control cells
- Co-treatment
- Monanchoxymycalin C (MomC); single agents were considered in combination analysis
- Reported limits
- No tested FR180204 salt, lot, purity, or final vehicle percentage specified in reviewed methods. Triplicate statement does not distinguish biological from technical replicates.
Methods and source locations
Compound reported in the paper: FR180204; Compound label in the paper: ERK1/2 inhibitor
Applies to the named research compound in this cell-line combination experiment; no salt conversion or Adooq lot equivalence.
Figure 6b (image labels); Supplementary Table S3; Methods: Determination of drug combination effects, Cell lines and culture conditions, Reagents and antibodies
MTT-derived combination effect: MomC 0.625 µM + FR180204 6.25 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 1.25 µM + FR180204 12.5 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 2.5 µM + FR180204 25.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 5.0 µM + FR180204 50.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 0.625 µM + FR180204 12.5 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 1.25 µM + FR180204 25.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 2.5 µM + FR180204 50.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis
MTT-derived combination effect: MomC 5.0 µM + FR180204 100.0 µM: Chou–Talalay analysis using CompuSyn v1.0; CI >1.1 antagonistic, 0.9–1.1 additive, <0.9 synergistic. General methods state experiments performed in triplicates; CI uncertainty not tabulated. — Supplementary Table S3; Figure 6b; Methods: Determination of drug combination effects and Statistical analysis